Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?

Key Points

• J&J shares rose 1.1% to approximately $273.11, despite trading volume running 34% below the average session level.
• The outlook is supported by EU approval for a TECVAYLI combination, pipeline momentum, recent revenue and earnings beats, and largely bullish analyst ratings. However, Stelara revenue erosion and ongoing talc litigation—including a proposed $5.5 billion settlement and a recent $10 million verdict—remain key risks.
• J&J reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75 and declared a quarterly dividend of $1.34 per share, equivalent to a 2.0% annualized yield.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s share price traded up 1.1% during trading on Monday . The company traded as high as $273.98 and last traded at $273.1140. 5,411,035 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 8,241,688 shares. The stock had previously closed at $270.24.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The European Commission approved a TECVAYLI combination for multiple myeloma, expanding access to J&J’s oncology portfolio and potentially supporting future pharmaceutical sales. Johnson & Johnson Wins EU Approval for TECVAYLI Combo
• Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including new product launches, late-stage clinical data and additional approvals. These catalysts could help offset the loss of exclusivity affecting older drugs and support growth through 2026 and beyond. J&J’s Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead
• Positive Sentiment: Recent comparisons with other healthcare companies characterized J&J as a relatively defensive business with growth potential from its pharmaceutical and medical-technology operations. Its latest reported quarter also showed revenue growth and an earnings beat, while full-year 2026 EPS guidance remains $11.60–$11.75.
• Neutral Sentiment: J&J’s proposed $5.5 billion settlement covering tens of thousands of talc-related ovarian-cancer claims could improve visibility into a long-running liability, but the settlement is not a complete resolution of the company’s legal exposure. J&J’s $5.5 Billion Talc Settlement
• Negative Sentiment: A Louisiana jury awarded $10 million in a talc-related mesothelioma case involving a former user of J&J talc products. Although the award is small relative to J&J’s market capitalization, it reinforces continuing litigation and headline risk. Louisiana Jury Issues $10 Million Verdict
• Negative Sentiment: J&J is already experiencing rapid erosion of Stelara revenue as competitors and biosimilars challenge the drug after loss of exclusivity. Investors must therefore determine whether newer medicines and pipeline products can replace the declining franchise. Pfizer vs. Johnson & Johnson Patent Cliff Comparison

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Citigroup increased their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Scotiabank reissued an "outperform" rating and issued a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Finally, TD Cowen increased their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $268.22.

Johnson & Johnson Price Performance

The company has a market cap of $658.18 billion, a price-to-earnings ratio of 31.65, a P/E/G ratio of 2.58 and a beta of 0.24. The company's 50-day simple moving average is $255.08 and its 200-day simple moving average is $242.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Insiders Place Their Bets

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 63,972 shares of company stock valued at $16,245,605. Corporate insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of JNJ. Blueline Advisors LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $26,000. Outlook Capital Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $28,000. DecisionPoint Financial LLC grew its position in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Finally, Bay Harbor Wealth Management LLC increased its stake in shares of Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after purchasing an additional 49 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source